Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

6.675 -0.185 (-2.70%)
Streaming Delayed Price Updated: 1:04 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioCryst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Stocks Rally as Major Indexes Look to End Losing Streaks
All three major indexes are set to snap three consecutive weeks of losses on Friday, as stocks surge midday. 
Via Talk Markets
BioCryst Gets FDA Fast Track Designation For Bone Formation Disorder Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BioCryst Pharmaceuticals's (NASDAQ: BCRX) lead drug candidate BCX9250 for the prevention of heterotopic ossification... 
Via Benzinga
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
7 Cheap Biotech Stocks to Buy Now
These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains. 
Via InvestorPlace
BioCryst's Voluntary Pause Of Rare Blood Disorder Trial Turns Into FDA Clinical Hold
 
Via Benzinga
Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood Disorder
 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: BioCryst Pharmaceuticals Q1 Earnings
BioCryst Pharmaceuticals (NASDAQ:BCRX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
7 Top-Rated Biotech Stocks to Buy for Q2
In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill. 
Via InvestorPlace
What 4 Analyst Ratings Have To Say About BioCryst Pharmaceuticals
Within the last quarter, BioCryst Pharmaceuticals (NASDAQ:BCRX) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022
Upgrades 
Via Benzinga
28 Biggest Movers From Yesterday
Gainers HighPeak Energy, Inc. (NASDAQ: HPK) shares gained 31.76% to close at $28.83 on Wednesday, after CNBC’s Jim Cramer said the mid-cap company is an aggressive play on... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Oppenheimer Maintains Outperform Rating for BioCryst Pharmaceuticals, Lowers Price Target To $16
Oppenheimer has decided to maintain its Outperform rating of BioCryst Pharmaceuticals (NASDAQ:BCRX) and lower its price target from $20.00 to $16.00. Shares of BioCryst Pharmaceuticals are trading down... 
Via Benzinga
Why BioCryst Pharmaceuticals Stock Is Falling
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Monday morning after BofA Securities downgraded the stock and Oppenheimer lowered its price target.  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2022
Upgrades 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Falls 150 Points; Crude Oil Rises 2%
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dropping more than 100 points on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Phio Pharma (NASDAQ:PHIO) shares increased by 46.7% to $1.33 during Friday's regular session. As of 13:31 EST, Phio Pharma's stock is trading at a volume... 
Via Benzinga
28 Stocks Moving In Friday's Mid-Day Session
Gainers Lyra Therapeutics, Inc. (NASDAQ: LYRA) shares climbed 33.3% to $5.78 as the company reported a private placement for gross proceeds of $110.5 million. TSR, Inc. (NASDAQ... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Mid-Day Market Update: Dow Jumps Over 200 Points; Sunshine Biopharma Shares Slide
U.S. stocks traded mixed midway through trading, with the Dow Jones surging more than 200 points on Friday. 
Via Benzinga
Mid-Morning Market Update: Markets Edge Lower; US Wholesale Inventories Rise 2.5% In February
U.S. stocks traded mostly lower this morning, with the Nasdaq Composite dropping 100 points on Friday. 
Via Benzinga
Why BioCryst Pharmaceuticals Stock Is Plunging Today
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading significantly lower Friday after the company paused enrollment in clinical trials with BCX9930 while it ... 
Via Benzinga
Biocryst Pharmaceuticals Stock Shows Rising Price Performance With Jump To 92 RS Rating
Biotech Biocryst Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 88 to 92 Wednesday. 
Via Investor's Business Daily
BioCryst Continues To Develop A Strong Pipeline
Investing in biotech stocks often comes with huge risks and rewards, as a company is dependent on its pipeline and royalty payments. 
Via Talk Markets
BioCryst's Orladeyo Shows Long Term Benefit With Sustained Reductions in Attack Rates
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) announced new long-term efficacy and safety data from the APeX-2 trial evaluating Orladeyo (berotralstat) for the... 
Via Benzinga
Recap: BioCryst Pharmaceuticals Q4 Earnings
BioCryst Pharmaceuticals (NASDAQ:BCRX) reported its Q4 earnings results on Wednesday, February 23, 2022 at 07:00 AM. Here's what investors need to know about the... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.